Interpace Q2 revenue $11.2M (+105% YoY); gross margin 48% vs 29%, adj EBITDA loss narrows to $0.3M

INTERPACE BIOSCIENCES, INC.

Net revenue $11.2M (+105% vs Q2 2020); six-month revenue $21.0M (+45% YoY).
Gross profit margin 48% (Q2 2020: 29%); loss from continuing ops improved to $3.4M from $5.5M.
Adjusted EBITDA $(0.3)M vs $(4.2)M in prior year; cash collections hit $11.5M in Q2, DSO down 32%.
Cash balance rose to $4.0M at July 31 from $2.8M at Dec 31, 2020; on track for >35% FY revenue growth.
New PLA code 0245U for ThyGeNEXT at $2,919; eviCore coverage for ThyGeNEXT/ThyraMIR effective July 1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.